AVDL - Avadel Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD

Avadel Pharmaceuticals plc

Blanchardstown Corporate Park
Block 10-1 Ballycoolin
Dublin 15
353 1 485 1200

IndustryDrug Manufacturers - Specialty & Generic
Full Time Employees144

Key Executives

NameTitlePayExercisedYear Born
Mr. Michael F. KananSr. VP & CFO477.05kN/A1963
Mr. Phillandas T. ThompsonSr. VP, Gen. Counsel & Corp. Sec.450.38kN/A1974
Mr. Gregory J. DivisVP of Corp. and Bus. Devel.486.93kN/A1965
Ms. Sandra L. HattenSr. VP of Quality & Regulatory Affairs380.79kN/A1957
Mr. Gregory J. Divis Jr.CEO & DirectorN/AN/A1967
Amounts are as of December 31, 2018 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Corporate Governance

Avadel Pharmaceuticals plc’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.